Published: 6/7/2022 10:50:57 AM

Respiratorius: Focusing on VAL001 - Redeye

Redeye returns with an updated assessment of Respiratorius as its divestment of RCD405 and other COPD assets transform the company into a pure orphan oncology case on the verge of a potential near-term deal with key asset VAL001.

Link to the analysis

Read more about Respiratorius AB